Stock comparison
Harmony Biosciences Holdings
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 46D | HRMY |
| Benjamin Graham | 60C | 60D | Tie |
| Philip Fisher | 75B | 59C | HRMY |
| Peter Lynch | 62C | 53C | HRMY |
| Joel Greenblatt | 28F | 49D | TEVA |
| Charlie Munger | 62C | 50D | HRMY |
| Terry Smith | 67B | 41D | HRMY |
Side-by-side metrics
| Metric | HRMY | TEVA |
|---|---|---|
| Market cap | $1.75B | $39.67B |
| P/E (TTM) | 11.8x | 25.4x |
| EV/EBIT | 6.4x | 24.8x |
| ROIC (TTM) | 12.5% | 11.49% |
| Gross margin | 76.55% | 51.98% |
| Net margin | 16.2% | 9.03% |
| Revenue CAGR 5y | 29.85% | 2.1% |
| EPS CAGR 5y | 46.45% | 34.13% |
| Debt / Equity | 0.2x | 2.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- Revenue CAGR 5y29.85%vs 2.1%+93%
- Debt / Equity0.2xvs 2.1x+89%
- EV/EBIT6.4xvs 24.8x+74%
- P/E (TTM)11.8xvs 25.4x+53%
TEVA leads on
- Market cap$39.67Bvs $1.75B+96%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.